Table 2. Hazard ratios and 95% confidence intervals for associations between prediagnostic serum LDH and risk of death following cancer diagnosis.
|
LDH |
|||
|---|---|---|---|
| Z-score | ⩽ULN | >ULN | |
|
All-cause death | |||
| No. of deaths/all patients | 5187/7216 | 612/679 | |
| Age adjusted | 1.18 (1.16–1.21) | 1.0 (Ref) | 1.78 (1.64–1.94) |
| Multivariablea | 1.16 (1.14–1.19) | 1.0 (Ref) | 1.66 (1.53–1.81) |
| Stratified by cancer sitea | 1.12 (1.10–1.15) | 1.0 (Ref) | 1.43 (1.31–1.56) |
| Sampling ⩽3 months before diagnosisb | 1.15 (1.12–1.18) | 1.0 (Ref) | 1.91 (1.65–2.20) |
|
Cancer-specific death | |||
| No. of deaths/all patients | 3760/7216 | 462/679 | |
| Age adjusted | 1.19 (1.17–1.22) | 1.0 (Ref) | 1.85 (1.68–2.03) |
| Multivariablea | 1.17 (1.14–1.20) | 1.0 (Ref) | 1.72 (1.56–1.90) |
| Stratified by cancer sitea | 1.12 (1.10–1.15) | 1.0 (Ref) | 1.46 (1.32–1.61) |
| Sampling ⩽3 months before diagnosisb | 1.17 (1.12–1.20) | 1.0 (Ref) | 2.06 (1.76–2.41) |
Abbreviations: LDH=lactate dehydrogenase; Ref=reference; ULN=upper limit of normal.
a
Adjusted for age at diagnosis, sex, socioeconomic status, Charlson comorbidity index and period of diagnosis.
b
Subanalysis in 1657 participants. Adjusted for age at diagnosis, sex, socioeconomic status, Charlson comorbidity index, period of diagnosis and stratified by cancer site.